Filing identity and reporting period
Important identity mismatch: The supplied filing is Venaxis, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2013, not a Riot Platforms, Inc. filing. The summary below describes the supplied Venaxis filing.
Business context and financial results
Venaxis was developing APPY1, an acute appendicitis diagnostic test, and pursuing FDA clearance and commercialization in Europe following CE marking. The company reported recurring operating losses and negative operating cash flow.
| Metric | Q1 2013 | Q1 2012 |
|---|---|---|
| Sales | $0 | $7,275 |
| Other license-fee revenue | $18,655 | $0 |
| Operating expenses | $2.840 million | $1.881 million |
| Operating loss | $2.821 million | $1.874 million |
| Net loss | $2.802 million | $1.938 million |
| Basic and diluted loss per share | $0.28 | $1.21 |
| Net cash used in operations | $2.472 million | $1.735 million |
No gross margin was reported in 2013 because there were no sales or cost of sales. Cash and cash equivalents were $2.492 million at quarter-end; short-term investments were $6.776 million, for combined cash and liquid investments of approximately $9.268 million. Working capital was approximately $6.335 million. Total debt and other obligations were $2.692 million, including $1.945 million current. The filing does not provide a conventional debt-to-equity covenant or leverage ratio.
Changes versus the prior comparable period
- Operating expenses rose by approximately $959,000. R&D increased 109% to $1.412 million, mainly due to APPY1 clinical-trial activity; SG&A increased 19% to $1.428 million, including higher commercialization, marketing, and legal costs.
- Operating cash use increased by approximately $737,000. The company spent $5.613 million purchasing short-term investments, a shift of cash into investments rather than operating expenditure.
- Cash and cash equivalents fell from $10.978 million at year-end 2012 to $2.492 million; short-term investments rose from $1.163 million to $6.776 million.
- Loss per share improved from $1.21 to $0.28, while weighted average shares rose from 1.608 million to 9.954 million. The filing attributes the share-count change to 2012 share issuances after the prior-year period; historical share data reflects a 1-for-6 reverse split.
Outlook, risks, and unusual items
- Management expected continued near-term losses, potentially significant, and said available working capital was expected to fund needs through the remainder of 2013 and at least into 2014. It was pursuing additional financing; failure to obtain capital could require reduced R&D or cessation of operations.
- A commercial-bank mortgage balloon payment of approximately $1.6 million was due in July 2013. After quarter-end, the company received a lender commitment to refinance; proposed terms included a 3.95% fixed rate and five-year maturity. Closing was expected before July, but was not assured in this filing.
- Management planned to advance APPY1 development and FDA trial activities, support European commercialization, pursue financing and licensing opportunities, and control costs. Planned 2013 capital expenditures were approximately $75,000–$125,000.
- The animal-health license agreement provided for a $204,000 payment due June 2013, potential milestones, and royalties; these future amounts depended on contractual conditions and milestones.
- The Wolfe securities class action was on appeal after dismissal without prejudice; the company said it intended to continue defending the claims. A related derivative action was administratively closed, subject to reopening. Management said no other pending legal proceeding was expected to have a material adverse effect.
- Unusual items included approximately $50,000 of income from redemption of a mutual insurance company and $484,000 of stock-based compensation. No income tax benefit was recorded on the loss.
Most important facts for investors to verify
- Confirm the issuer: this document names Venaxis, Inc., not Riot Platforms, Inc.
- Track cash burn and liquid resources, including the distinction between cash and short-term investments, and whether financing became necessary.
- Verify whether the July 2013 mortgage refinancing closed on the proposed terms and whether the payment due under the Novartis termination obligation was made.
- Assess APPY1 clinical-trial progress, FDA clearance prospects, and European commercialization; the filing identifies failure to secure clearance or sufficient revenue as material business risks.
- Check subsequent status of the securities-litigation appeal and potential animal-health license payments and milestones.